卡瑞利珠单抗联合TP方案治疗晚期食管癌的临床研究  

Clinical Study of Carrelizumab Combined with TP Regimen in the Treatment of Advanced Esophageal Cancer

作　　者：陈慧芳 CHEN Huifang(General Hospital of Pingmei Shenma Medical Group,Pingdingshan,467000)

机构地区：[1]平煤神马医疗集团总医院,467000

出　　处：《实用癌症杂志》2023年第3期491-495,共5页The Practical Journal of Cancer

摘　　要：目的 探讨晚期食管癌患者采用卡瑞利珠单抗联合TP方案(顺铂+紫杉醇)治疗的临床效果。方法 对92例晚期食管癌患者进行前瞻性随机对照研究,随机分为对照组(46例)与观察组(46例),对照组采用TP方案治疗,观察组采用卡瑞利珠单抗+TP方案治疗,21 d为1个疗程,连续治疗4个疗程。治疗结束后1个月后评估2组临床疗效,对比2组治疗前、治疗结束后1个月时血清肿瘤标志物水平[癌胚抗原(CEA)、高迁移率族蛋白B1(HMGB1)、鳞状细胞癌相关抗原(SCC-Ag)]、自然杀伤(NK)细胞、T淋巴细胞亚群,并统计2组治疗期间不良反应。结果 观察组临床总有效率高于对照组,差异有统计学意义(P<0.05);治疗结束后1个月时,观察组CEA、HMGB1、SCC-Ag水平低于对照组,NK细胞、CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)高于对照组,CD_(8)^(+)低于对照组,差异有统计学意义(P<0.05)。2组不良反应比较,差异无统计学意义(P>0.05)。结论 采用卡瑞利珠单抗联合TP方案治疗晚期食管癌可降低患者血清肿瘤标志物水平,减轻对免疫力的损害,提高临床疗效,且不会增加不良反应。Objective To investigate the clinical effect of carrelizumab combined with TP regimen(cisplatin+paclitaxel) in patients with advanced esophageal cancer.Methods A prospective randomized controlled study was conducted on 92 patients with advanced esophageal cancer.They were randomly divided into the control group(46 cases) and the observation group(46 cases).The control group was treated with TP regimen, and the observation group was treated with carrelizumab+TP regimen.21 days was a course of treatment, with 4 consecutive courses of treatment.The clinical efficacy of the 2 groups was evaluated 1 month after the end of treatment.The levels of serum tumor markers [carcinoembryonic antigen(CEA),high mobility group protein B1(HMGB1),squamous cell carcinoma associated antigen(SCC-Ag)],natural killer(NK) cells, and T lymphocyte subsets were compared before treatment and one month after the end of treatment, and the adverse reactions of the 2 groups during treatment were counted.Results The total clinical effective rate of the observation group was higher than that of the control group, and the difference was statistically significant(P<0.05).One month after the treatment, the levels of CEA,HMGB1 and SCC-Ag in the observation group were lower than those in the control group, the levels of NK cells, CD_(4)^(+),CD_(4)^(+)/CD_(8)^(+)were higher than those in the control group, and the levels of CD_(8)^(+)were lower than those in the control group, the difference was statistically significant(P<0.05).There was no statistical significant difference in adverse reactions between the 2 groups(P>0.05).Conclusion Carrelizumab combined with TP regimen in the treatment of advanced esophageal cancer can reduce the level of serum tumor markers, reduce the damage to immunity, improve clinical efficacy, and will not increase adverse reactions.

关 键 词：食管癌 卡瑞利珠单抗 顺铂 紫杉醇 

分 类 号：R735.1[医药卫生—肿瘤]